Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Dow
Medtronic
Merck
Boehringer Ingelheim

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,435,944

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,435,944 protect, and when does it expire?

Patent 8,435,944 protects AXIRON and is included in one NDA.

This patent has nineteen patent family members in thirteen countries.

Summary for Patent: 8,435,944
Title:Method and composition for transdermal drug delivery
Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.
Inventor(s): Dipietro; Tony (Victoria, AU), Humberstone; Andrew (Victoria, AU), Gonda; Igor (South Yarra, AU), Watkinson; Adam (Victoria, AU), Setiawan; Kerrie (Victoria, AU), Wilkins; Nina (Victoria, AU)
Assignee: Acrux DDS Pty Ltd. (West Melbourne, Victoria, AU)
Application Number:11/445,463
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,435,944
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Device;

Drugs Protected by US Patent 8,435,944

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 DISCN Yes No   Start Trial   Start Trial A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,435,944

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2005902902Jun 03, 2005

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
McKinsey
AstraZeneca
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.